Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout

• Published in: The Annals of pharmacotherapy Vol. 51; no. 4; p. 301
• Main Authors: Hughes, Jonathan C, Wallace, Jessica L, Bryant, Candace L, Salvig, Brent E, Fourakre, T Neal, Stone, William J
• Format: Journal Article
• Language: English
• Published: United States 01.04.2017
• Subjects: Adult; Aged; Allopurinol - administration & dosage; Allopurinol - adverse effects; Allopurinol - therapeutic use; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Drug Monitoring; Febuxostat - administration & dosage; Febuxostat - adverse effects; Febuxostat - therapeutic use; Female; Gout - blood; Gout - drug therapy; Gout Suppressants - administration & dosage; Gout Suppressants - adverse effects; Gout Suppressants - therapeutic use; Humans; Male; Retrospective Studies; Rheumatology; Tennessee; Uric Acid - blood; Veterans; Xanthine Oxidase - antagonists & inhibitors; rheumatology; adherence; quality assurance; therapeutic monitoring; gout
• ISSN: 1542-6270
• DOI: 10.1177/1060028016679848

With the prevalence of and hospitalizations for gout increasing, optimizing care for patients with gout is imperative. The 2012 American College of Rheumatology gout guidelines emphasize that timely monitoring is key to achieving serum urate (SUA) goals. Few studies have examined this metric following the 2012 update, and to our knowledge, none have examined a veteran population. To evaluate adherence to urate-lowering therapy (ULT) monitoring guidelines in a veteran population. This is a single-center, multisite, retrospective chart review of US veterans receiving ULT for gout within the VA (Veterans Affairs) Tennessee Valley Healthcare System from January 1, 2013, to June 30, 2015. The primary end point was percentage of patients with a SUA within 6 months of initial xanthine oxidase inhibitor prescription. Secondary end points included percentage of patients with SUA <6 mg/dL and percentage of patients with uptitration following SUA above goal. A total of 601 patients met inclusion criteria for the study; after application of exclusion criteria, 505 were analyzed. Of these, 295 patients (58%) did not have a SUA drawn within 6 months, and 162 patients (32%) reached the end of the study period without SUA measured. Of 226 patients with SUA above goal on initial check, 64 (28%) had timely dose adjustment, whereas 143 patients (63%) had no adjustment. A total of 161 patients (32%) had a SUA at goal within the study period. Rates of ULT monitoring at a major VA medical center were suboptimal, and improved adherence to guideline recommendations is needed.